


Corporate Funding is Agile September 5, 2018



© Debiopharm Group









Investing in future patient care

- Strategic investment fund of the Debiopharm Group
- With an investment focus on :



Smart data





• In the areas of oncology and infectious disease



Debiopharm Innovation Fund



- **\$100m** invested in **12** companies since 2008
- We led **12/15** last rounds of financing
- Performance to date: 2 IPOs and 18 products obtained FDA clearance or CE mark.



Smart data	Diagnostics		Pharma
BC [§] Platforms	BIOCARTIS	Immunexpress	ABAC Therapeutics
Kaiku HEALTH	○ GenePOC [™]		Effimune
	spinomix	🐼 diagno plex	Eclosion ²



Looking for investment opportunities in smart data



- Smart data, digital health companies
- Applications strongly focused on improving patient journey or drug development, with the help of big data, AI and digital tools
 - Patient monitoring
 - Clinical decision support systems
 - Digital therapeutics
 - Digital biomarkers
 - Digital patient recruitment, digital trials
 - Digital drug development tools
- In oncology or infectious disease areas or with an expansion potential into them
- Company should be in piloting or early commercial stage

Smart data investment scope Series A, B and C First bite \$ 1- 10 m 15-20% stake Active board participation



Corporate venture funding



Oh hi Jim – you're here too!






- Maintaining competitiveness as a mid-size pharma requires innovativeness and agility
- Flexible ways for collaborating with the outside world in the past 12 months:
 - Licensing of preclinical asset from Almac Discovery
 - Acquisition of phase II asset from Immunogen
 - Option to license a novel radiotherapeutic from a research institute
 - Investment in ABAC Therapeutics












- 1) Not only money value from expertise & resources
- 2) CVC's are patient investors, no timeline pressure from fund lifecycle
- 3) Especially in Europe, more corporate venture money than VC money available for early stage investments








Debiopharm Innovation Fund balance between strategic vs. financial goals







What about the Chinese wall?







Why do we need to be agile?

	Trends	
 Market trends Patients are becoming better informed Patients are picking up a bigger share of the bill Demand for personalised medicine is increasing Patients want cures, not treatments The emerging markets are becoming more important 	 Health and healthcare trends The burden of – and bill for – chronic disease is soaring Healthcare payers are establishing treatment protocols Pay-for-performance is on the rise The boundaries between different forms of care are blurring Financial constraints on payers are increasing 	 Scientific and technological trends R&D is becoming more virtualised The research base is shifting to Asia Remote monitoring is improving rapidly
	Implications	
Pharma will need to go "beyond the medicine"	R&D will need to go beyond the lab	The Pharma and healthcare value chains will become much more intertwined
 Pharma will be paid for outcomes, not products Outcomes data will drive healthcare policy Prevention will gain a higher healthcare profile 	 Pharma will need access to outcomes data Pharma will have to work with technology vendors to virtualise R&D Pharma will need a wider, more multi-disciplinary skills base 	 Pharma will have to work more closely with the regulators Pharma will have to collaborate with payers and providers to perform continuous trials Pharma will have to collaborate with

 Pharma will have to adopt more flexible pricing strategies

Business models based on collaboration

• Pharma will need to demonstrate "real"

value-for-money



Change management: 1998 vs. 2018



1998: Bigger is better!

We were in the middle of intense M&A period

- Ciba-Geigy and Sandoz had just merged
- Astra and Zeneca, GlaxoWellcome and SmithKline Beecham were still separate companies.

We were having a time of our lives with blockbusters

- Lipitor and Plavix were just launched
- Abilify was still in development
- Small molecules for primary care was hot

Focus on USA and Europe

2018: Lean and mean!

Divesting to have better focus

- Exiting non-aligned portfolios
- Asset-swapping
- ... or diversifying under one umbrella...

R&D productivity big topic

- R&D restructuring
- Narrow-scope acquisitions
- Partnerships
- Specialty and biologics are hot

Geographic expansion





Siri states that the world will end in 2038.

© UberFacts 2015



In-depth understanding of medical and health care industry

- Deep pharma resources
- Diagnostics and medtech markets
- Regulatory policies
- Health economics and reimbursement knowledge
- Clinical sciences, oncology, infectious diseases

Experience in growing small companies





We look forward to speaking with you!



Tanja Dowe CEO



Tom Gibbs Director



Bea Arnold Associate Director



Denis Robichon Consultant



Nici Wilson Senior Administrative Assistant



Contact information

TANJA DOWE CEO Debiopharm Innovation Fund Debiopharm Innovation Fund SA tanja.dowe@debiopharm.com

Debiopharm Group™ Headquarters Lausanne, Switzerland www.debiopharm.com